Sustained release formulation for venlafaxine hydrochloride

Details for Australian Patent Application No. 2004258732 (hide)

Owner Pharmathen S.A.

Inventors Politis, Stavros; Karavas, Evangelos; Lioumis, Konstantinos

Agent Spruson & Ferguson

Pub. Number AU-B-2004258732

PCT Pub. Number WO2005/009414

Priority 03386019.8 30.07.03 EP

Filing date 23 July 2004

Wipo publication date 3 February 2005

Acceptance publication date 11 June 2009

International Classifications

A61K 9/48 (2006.01) Medicinal preparations characterised by special physical form - Preparations in capsules, e.g. of gelatin, of chocolate

A61K 9/52 (2006.01) Medicinal preparations characterised by special physical form - Sustained or differential release type

A61K 31/137 (2006.01) - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine

Event Publications

23 February 2006 PCT application entered the National Phase

  PCT publication WO2005/009414 Priority application(s): WO2005/009414

27 November 2008 Amendment Made

  The nature of the amendment is: Amend the invention title to read from Sutained release formulation for venlafaxine hydrochloride to Sustained release formulation for venlafaxine hydrochloride

11 June 2009 Application Accepted

  Published as AU-B-2004258732

8 October 2009 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004258736-Treatment of lesions of the soft tissues

2004258731-Bacteriophage-containing therapeutic agents